Targeted Inhibition of Calpain Reduces Myocardial Hypertrophy and Fibrosis in Mouse Models of Type 1 Diabetes

OBJECTIVE Recently we have shown that calpain-1 activation contributes to cardiomyocyte apoptosis induced by hyperglycemia. This study was undertaken to investigate whether targeted disruption of calpain would reduce myocardial hypertrophy and fibrosis in mouse models of type 1 diabetes. RESEARCH DESIGN AND METHODS Diabetes in mice was induced by injection of streptozotocin (STZ), and OVE26 mice were also used as a type 1 diabetic model. The function of calpain was genetically manipulated by cardiomyocyte-specific knockout Capn4 in mice and the use of calpastatin transgenic mice. Myocardial hypertrophy and fibrosis were investigated 2 and 5 months after STZ injection or in OVE26 diabetic mice at the age of 5 months. Cultured isolated adult mouse cardiac fibroblast cells were also investigated under high glucose conditions. RESULTS Calpain activity, cardiomyocyte cross-sectional areas, and myocardial collagen deposition were significantly increased in both STZ-induced and OVE26 diabetic hearts, and these were accompanied by elevated expression of hypertrophic and fibrotic collagen genes. Deficiency of Capn4 or overexpression of calpastatin reduced myocardial hypertrophy and fibrosis in both diabetic models, leading to the improvement of myocardial function. These effects were associated with a normalization of the nuclear factor of activated T-cell nuclear factor-κB and matrix metalloproteinase (MMP) activities in diabetic hearts. In cultured cardiac fibroblasts, high glucose–induced proliferation and MMP activities were prevented by calpain inhibition. CONCLUSIONS Myocardial hypertrophy and fibrosis in diabetic mice are attenuated by reduction of calpain function. Thus targeted inhibition of calpain represents a potential novel therapeutic strategy for reversing diabetic cardiomyopathy.

[1]  Yongjian Yang,et al.  Increased expression of calpain and elevated activity of calcineurin in the myocardium of patients with congestive heart failure. , 2010, International journal of molecular medicine.

[2]  T. Peng,et al.  Deficiency of Rac1 Blocks NADPH Oxidase Activation, Inhibits Endoplasmic Reticulum Stress, and Reduces Myocardial Remodeling in a Mouse Model of Type 1 Diabetes , 2010, Diabetes.

[3]  Kim Van der Heiden,et al.  Role of nuclear factor kappaB in cardiovascular health and disease. , 2010, Clinical science.

[4]  K. Otsu,et al.  Cardiac fibroblasts are essential for the adaptive response of the murine heart to pressure overload. , 2010, The Journal of clinical investigation.

[5]  R. Dietz,et al.  NF-kappaB activation is required for adaptive cardiac hypertrophy. , 2009, Cardiovascular research.

[6]  T. Peng,et al.  Calpain activation contributes to hyperglycaemia-induced apoptosis in cardiomyocytes. , 2009, Cardiovascular research.

[7]  M. Zile,et al.  Calpain inhibition preserves myocardial structure and function following myocardial infarction. , 2009, American journal of physiology. Heart and circulatory physiology.

[8]  T. Peng,et al.  Over-expression of calpastatin inhibits calpain activation and attenuates myocardial dysfunction during endotoxaemia. , 2009, Cardiovascular research.

[9]  B. Ehrlich,et al.  Calcium, calpains, and cardiac hypertrophy: a new link. , 2009, Circulation research.

[10]  R. Schulz,et al.  Protective action of doxycycline against diabetic cardiomyopathy in rats , 2008, British journal of pharmacology.

[11]  T. Peng,et al.  JNK1/c-fos inhibits cardiomyocyte TNF-alpha expression via a negative crosstalk with ERK and p38 MAPK in endotoxaemia. , 2008, Cardiovascular research.

[12]  R. Campbell,et al.  Calcium-bound structure of calpain and its mechanism of inhibition by calpastatin , 2008, Nature.

[13]  X. Wehrens,et al.  NFATc2 Is a Necessary Mediator of Calcineurin-dependent Cardiac Hypertrophy and Heart Failure* , 2008, Journal of Biological Chemistry.

[14]  A. Vaag,et al.  Diabetes Patients Requiring Glucose-Lowering Therapy and Nondiabetics With a Prior Myocardial Infarction Carry the Same Cardiovascular Risk: A Population Study of 3.3 Million People , 2008, Circulation.

[15]  E. Letavernier,et al.  Targeting the Calpain/Calpastatin System as a New Strategy to Prevent Cardiovascular Remodeling in Angiotensin II–Induced Hypertension , 2008, Circulation research.

[16]  T. Pozzan,et al.  Ca2+ oscillation frequency decoding in cardiac cell hypertrophy: Role of calcineurin/NFAT as Ca2+ signal integrators , 2008, Proceedings of the National Academy of Sciences.

[17]  David C. Young,et al.  Prevention of Cardiac Hypertrophy and Heart Failure by Silencing of NF-κB , 2008 .

[18]  D. Kass,et al.  Small-molecule therapies for cardiac hypertrophy: moving beneath the cell surface , 2007, Nature Reviews Drug Discovery.

[19]  E. Abel,et al.  Diabetic cardiomyopathy revisited. , 2007, Circulation.

[20]  S. Anker,et al.  Contributions of Inflammation and Cardiac Matrix Metalloproteinase Activity to Cardiac Failure in Diabetic Cardiomyopathy , 2007, Diabetes.

[21]  S. Tyagi,et al.  Homocysteine-mediated activation and mitochondrial translocation of calpain regulates MMP-9 in MVEC. , 2006, American journal of physiology. Heart and circulatory physiology.

[22]  G. Camussi,et al.  Calpain activation and secretion promote glomerular injury in experimental glomerulonephritis: evidence from calpastatin-transgenic mice. , 2006, Journal of the American Society of Nephrology : JASN.

[23]  P. Greer,et al.  Conditional disruption of ubiquitous calpains in the mouse , 2006, Genesis.

[24]  I. Poornima,et al.  Diabetic cardiomyopathy: the search for a unifying hypothesis. , 2006, Circulation research.

[25]  F. Villarreal,et al.  The pathogenesis of myocardial fibrosis in the setting of diabetic cardiomyopathy. , 2006, Journal of the American College of Cardiology.

[26]  M. Siebeck,et al.  Calpain inhibition reduces infarct size and improves global hemodynamics and left ventricular contractility in a porcine myocardial ischemia/reperfusion model. , 2005, European journal of pharmacology.

[27]  S. Cuzzocrea,et al.  Hyperglycemia in streptozotocin-induced diabetic rat increases infarct size associated with low levels of myocardial HO-1 during ischemia/reperfusion. , 2005, Diabetes.

[28]  David L. Williams,et al.  NF-κB activation is required for the development of cardiac hypertrophy in vivo , 2004 .

[29]  Thomas H Marwick,et al.  Diabetic cardiomyopathy: evidence, mechanisms, and therapeutic implications. , 2004, Endocrine reviews.

[30]  H. Sorimachi,et al.  Structure, activation, and biology of calpain. , 2004, Diabetes.

[31]  Jian Xu,et al.  Calcineurin/NFAT Coupling Participates in Pathological, but not Physiological, Cardiac Hypertrophy , 2004, Circulation research.

[32]  T. Peng,et al.  Inhibition of p38 MAPK decreases myocardial TNF-alpha expression and improves myocardial function and survival in endotoxemia. , 2003, Cardiovascular research.

[33]  S. Tyagi,et al.  Gelatinase B(MMP-9) an apoptotic factor in diabetic transgenic mice , 2003, Diabetologia.

[34]  D. E. Goll,et al.  The calpain system. , 2003, Physiological reviews.

[35]  P. Doevendans,et al.  Requirement of Nuclear Factor of Activated T-cells in Calcineurin-mediated Cardiomyocyte Hypertrophy* , 2002, The Journal of Biological Chemistry.

[36]  S. Krajewski,et al.  Calpain and Mitochondria in Ischemia/Reperfusion Injury* , 2002, The Journal of Biological Chemistry.

[37]  H. Taegtmeyer,et al.  Adaptation and maladaptation of the heart in diabetes: Part I: general concepts. , 2002, Circulation.

[38]  V. Petrov,et al.  Stimulation of Collagen Production by Transforming Growth Factor-&bgr;1 During Differentiation of Cardiac Fibroblasts to Myofibroblasts , 2002, Hypertension.

[39]  P. Greer,et al.  Reduced Cell Migration and Disruption of the Actin Cytoskeleton in Calpain-deficient Embryonic Fibroblasts* , 2001, The Journal of Biological Chemistry.

[40]  F. Spinale,et al.  Myocardial remodelling and matrix metallotxoteinases in heart failure: turmoil within the interstitium , 2001, Annals of medicine.

[41]  P. Greer,et al.  Disruption of the Murine Calpain Small Subunit Gene, Capn4: Calpain Is Essential for Embryonic Development but Not for Cell Growth and Division , 2000, Molecular and Cellular Biology.

[42]  B. Lowell,et al.  Cardiac hypertrophy with preserved contractile function after selective deletion of GLUT4 from the heart. , 1999, The Journal of clinical investigation.

[43]  Fei Chen,et al.  Calpain Contributes to Silica-Induced IκB-α Degradation and Nuclear Factor-κB Activation , 1997 .

[44]  S. Jimenez,et al.  Growth properties and biochemical characterization of collagens synthesized by adult rat heart fibroblasts in culture. , 1992, Journal of molecular and cellular cardiology.

[45]  S. Prabhu,et al.  Cardiomyocyte NF-κB p65 promotes adverse remodelling, apoptosis, and endoplasmic reticulum stress in heart failure. , 2011, Cardiovascular research.

[46]  T. Peng,et al.  Taurine prevents cardiomyocyte death by inhibiting NADPH oxidase-mediated calpain activation. , 2009, Free radical biology & medicine.

[47]  David C. Young,et al.  Prevention of cardiac hypertrophy and heart failure by silencing of NF-kappaB. , 2008, Journal of molecular biology.

[48]  A. Itai,et al.  Inhibition of NF-κB improves left ventricular remodeling and cardiac dysfunction after myocardial infarction , 2007 .

[49]  D. Lefer,et al.  Myocardial infarction and heart failure in the db/db diabetic mouse. , 2006, American journal of physiology. Heart and circulatory physiology.

[50]  David L. Williams,et al.  NF-kappaB activation is required for the development of cardiac hypertrophy in vivo. , 2004, American journal of physiology. Heart and circulatory physiology.

[51]  F. Chen,et al.  Calpain contributes to silica-induced I kappa B-alpha degradation and nuclear factor-kappa B activation. , 1997, Archives of biochemistry and biophysics.